Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, After Single and Multiple Intranasal Doses in Healthy Chinese SubjectsAn Open-Label, Single-Center, First-in-Human Study

被引：15
|
作者：
Luning Sun
Li Ding
Yongqing Wang
Wenjia Zhou
Zhengyu Yan
Weilin Sun
Hongwen Zhang
Ning Ou
Xiaoping Chen
机构：
[1] China Pharmaceutical University,
[2] First Affiliated Hospital of Nanjing Medical University,undefined
[3] Beijing Shiqiao Biological and Pharmaceutical Co. Ltd,undefined
来源：
Drugs in R&D | 2012年 / 12卷 / 1期
关键词：
Rhinitis; Intranasal Administration; Ipratropium Bromide; Lateral Nasal Wall; Aclidinium;
D O I：
10.2165/11599330-000000000-00000
中图分类号：
学科分类号：
摘要：
Background: Bencycloquidium bromide (BCQB) is a novel, potent and selective muscarinic M1/M3 receptor antagonist under development for the treatment of rhinorrhea in rhinitis. The pharmacokinetics and safety of BCQB in animals have been established in preclinical studies. However, no clinical pharmacokinetic data are available for BCQB in humans.
引用
收藏
页码：17 / 28
页数：11
相关论文
共 31 条
  • [21] A SINGLE-CENTER, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING SINGLE DOSES OF EMODEPSIDE (BAY44-4400) IN HEALTHY MALE SUBJECTS
    Gillon, Jean
    van den Berg, Frans
    Cheeseman, Karen
    Hopchet, Nathalie
    Delhomme, Sophie
    Rossi, Claudia
    Monnot, Frederic
    Strub-Wourgaft, Nathalie
    Rodriguez, Maria-Luisa
    Don, Rob
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2018, 99 (04): : 168 - 168
  • [22] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study
    Guehring, Hans
    Balchen, Torben
    Goteti, Kosalaram
    Sonne, Jesper
    Ladel, Christoph
    Ona, Victor
    Moreau, Flavie
    Bay-Jensen, Anne
    Bihlet, Asger Reinstrup
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [23] First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection
    Bergougnan, Luc
    Armani, Sara
    Golor, Georg
    Tardat, Agnes
    Vitse, Olivier
    Hurbin, Fabrice
    Scemama, Michel
    Poitiers, Franck
    Radzik, David
    Gaudin, Christophe
    Hovsepian, Lionel
    Muslin, Anthony J.
    Kirkesseli, Stephane
    Deutsch, Paul
    Parkar, Ashfaq A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (02) : 598 - 611
  • [24] A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants
    Feng, Sheng
    Gane, Edward
    Schwabe, Christian
    Zhu, Mingfen
    Triyatni, Miriam
    Zhou, Julian
    Bo, Qingyan
    Jin, Yuyan
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
  • [25] A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
    Lee, L.
    Hajireen, H.
    Ward, A.
    Firth, C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (09) : B19 - B19
  • [26] A FIRST-IN-HUMAN (FIH) STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE DOSES, AND ALTERNATIVE FORMULATIONS OF R941552 (R552), A SELECTIVE RECEPTOR INTERACTING PROTEIN 1 (RIP1) KINASE INHIBITOR.
    Yan, L.
    Park, G.
    Chow, D.
    Shaw, S.
    Blasingame, D.
    Singh, N.
    Zann, V.
    Chow, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S40 - S40
  • [27] Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study
    Nan-nan Chu
    Kai Huang
    Lin-Ling Que
    Ying Ding
    Xiang-hong Gu
    Lin Zhang
    Jia-kun Wang
    Xiao-ping Chen
    Zhan-guo Sun
    Qing He
    European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47 : 509 - 521
  • [28] Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study
    Chu, Nan-nan
    Huang, Kai
    Que, Lin-Ling
    Ding, Ying
    Gu, Xiang-hong
    Zhang, Lin
    Wang, Jia-kun
    Chen, Xiao-ping
    Sun, Zhan-guo
    He, Qing
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (04) : 509 - 521
  • [29] A Placebo-Controlled, Single-Blind, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Drug Interaction Of GSK1034702 (M1 Receptor Agonist) After Repeat Doses in Healthy Subjects for Up to 28 Days
    Lund, Jesper
    Dear, Gordon
    Lowy, Martin T.
    Graham, James
    BIOLOGICAL PSYCHIATRY, 2013, 73 (09) : 266S - 266S
  • [30] MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors
    Baird, Richard
    Omlin, Aurelius
    Kiemle-Kallee, Joachim
    Fiedler, Ulrike
    Zitt, Christof
    Feurstein, Daniel
    Herbst, Joerg
    Dawson, Keith
    vom Baur, Elmar
    Stumpp, Michael
    Hermann, Frank
    Harstrick, Andreas
    Schneeweiss, Andreas
    CANCER RESEARCH, 2018, 78 (04)
1234